跳轉至內容
Merck
全部照片(1)

重要文件

查看所有文件

SML0123

Sigma-Aldrich

Deflazacort

≥98% (HPLC)

同義詞:

(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-5′βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2′-acetate, DL-458-IT, L-5458, azacort, oxazacort, pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2′-methyloxazoline 21-acetate

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C25H31NO6
CAS號碼:
14484-47-0
分子量：:
441.52
EC號碼:
238-483-7
MDL號碼:
MFCD00866106
分類程式碼代碼:
51111800
PubChem物質ID:
329825173
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to tan

溶解度

DMSO: ≥20 mg/mL

儲存溫度

2-8°C

SMILES 字串

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C

InChI

1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

InChI 密鑰

FBHSPRKOSMHSIF-GRMWVWQJSA-N

基因資訊

human ... NR3C1(2908)

尋找類似的產品？ 前往 產品比較指南

生化／生理作用

Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
081M4724V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

David E Lebel et al.
The Journal of bone and joint surgery. American volume, 95(12), 1057-1061 (2013-06-21)
Duchenne muscular dystrophy, a progressive muscle disorder that occurs in males, causes a gradual decline in muscle strength. This progressive decline is associated with the development of scoliosis. Previous studies have shown that the use of glucocorticoids slows the progression
Walter Alberto Sifuentes Giraldo et al.
Reumatologia clinica, 8(4), 208-211 (2012-01-31)
Hypertrophic osteoarthropathy is an entity characterized by a triad of periostitis of long bones, clubbing and arthritis. Radiologically there are two patterns, one characterized by new bone formation which predominates in patients with pulmonary disease, and another by acro-osteolysis that
Luciano Merlini et al.
Muscle & nerve, 45(6), 796-802 (2012-05-15)
Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion. We performed a long-term study of alternate-day corticosteroids in five 2- to 4-year-old
Darlene L Machado et al.
BMC research notes, 5, 435-435 (2012-08-15)
Duchenne muscular dystrophy (DMD) is a sex-linked inherited muscle disease characterized by a progressive loss in muscle strength and respiratory muscle involvement. After 12 years of age, lung function declines at a rate of 6 % to 10.7 % per
Karen Uzark et al.
Pediatrics, 130(6), e1559-e1566 (2012-11-07)
The purpose of this study was to assess health-related quality of life (QoL) in children with Duchenne muscular dystrophy (DMD), including development and field-testing of a DMD-specific module integrated with the core Pediatric Quality of Life Inventory (PedsQL). The PedsQL
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務